KRAS and cancer: In this regard, a very recent work showed that the U2AF65-related protein RBM39, induced by treatment with an antineoplastic sulfonamide compound named Indisulam, selectively repressed expression of the splice variant A (KRAS4A) of the frequently mutated KRAS oncogene, which is enriched in cancer cells with stem-like properties.